<html>

        <head>
        <link href="../style1.css" rel="stylesheet" type="text/css">
        </head>
        <table border = 1>
        <tr>
        <th>PubMedID</th>
        <th>Sentence</th>
        <th>First Gene</th>
        <th>Second Gene</th>
        <th>Interaction</th>
        </tr>
        <body>
<tr class = "cellcolor">
<td>24285858</td>
<td>BACKGROUND: BRCA1 or BRCA2 mutations confer increased risks of breast and ovarian cancer, but risks have been found to vary across studies and populations</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24285858</td>
<td>METHODS: We ascertained pedigree data of 582 BRCA1 and 176 BRCA2 families and studied the variation in breast and ovarian cancer risks using a modified segregation analysis model</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24285729</td>
<td>BRCA1, BRCA2 and PALB2 are key players in cellular tolerance to chemotherapeutic  agents including camptothecin, cisplatin and poly[ADP ribose]polymerase inhibitor</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24277755</td>
<td>In addition, no data currently exist on the FRRs associated with EOC after exclusion of BRCA1 or BRCA2 mutation  carriers</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24277755</td>
<td>METHODS: EOC FRRs were computed from observed EOCs in relatives of 1548 patients  with EOC recruited between 1999 and 2010 from a population-based cohort study with known BRCA1 and BRCA2 mutation status and tumour subtype, compared with the  number expected in the general population</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24277755</td>
<td>The FRR to relatives of cases without a deleterious mutation in BRCA1 or BRCA2 was estimated to be over twice that of the general population (2.24 (95% CI 1.71 to 2.94))</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24277755</td>
<td>BRCA1 and BRCA2 mutations were estimated to account for about 24% of the EOC FRR to first-degree  relatives</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
<tr class = "cellcolor">
<td>24277377</td>
<td>Other  studies indicate that Aurora-A suppresses BRCA1, BRCA2, RAD51, poly(ADP ribose) polymerase (PARP), and gamma-H2AX to dysregulate DNA damage response</td>
<td>BRCA1</td>
<td>BRCA2</td>
<td>None</td>
</tr>
